A number of other research firms also recently issued reports on DBVT. HC Wainwright reaffirmed a buy rating and set a $25.00 price objective on shares of DBV TECHNOLOGIE/S in a report on Tuesday, October 8th. Zacks Investment Research raised shares of DBV TECHNOLOGIE/S from a sell rating to a hold rating in a report on Tuesday, November 5th. Finally, Oddo Bhf raised shares of DBV TECHNOLOGIE/S from a neutral rating to a buy rating in a report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $12.91.
DBVT traded up $0.01 during mid-day trading on Friday, reaching $8.55. 254,886 shares of the stock were exchanged, compared to its average volume of 310,752. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.96 and a current ratio of 3.00. The stock has a market capitalization of $738.47 million, a PE ratio of -2.52 and a beta of 1.79. The company has a 50 day moving average price of $7.54 and a two-hundred day moving average price of $8.67. DBV TECHNOLOGIE/S has a 1 year low of $3.60 and a 1 year high of $15.37.
Several large investors have recently modified their holdings of DBVT. Perceptive Advisors LLC boosted its holdings in shares of DBV TECHNOLOGIE/S by 219.8% in the 2nd quarter. Perceptive Advisors LLC now owns 3,609,084 shares of the company’s stock worth $29,666,000 after buying an additional 2,480,560 shares during the last quarter. Boxer Capital LLC boosted its holdings in shares of DBV TECHNOLOGIE/S by 26.2% in the 2nd quarter. Boxer Capital LLC now owns 5,300,000 shares of the company’s stock worth $43,566,000 after buying an additional 1,100,000 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of DBV TECHNOLOGIE/S by 142.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 417,064 shares of the company’s stock worth $3,587,000 after buying an additional 245,364 shares during the last quarter. Premier Asset Management LLC purchased a new position in shares of DBV TECHNOLOGIE/S in the 2nd quarter worth about $1,052,000. Finally, Morgan Stanley boosted its holdings in shares of DBV TECHNOLOGIE/S by 1.5% in the 2nd quarter. Morgan Stanley now owns 3,871,340 shares of the company’s stock worth $31,823,000 after buying an additional 57,117 shares during the last quarter. 32.91% of the stock is currently owned by institutional investors.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Story: What is a stock split?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.